Cargando…

A Paradigm Shift in the Management Approaches of Proliferative Diabetic Retinopathy: Role of Anti-VEGF Therapy

Diabetic retinopathy (DR) is considered one of the leading causes of vision loss globally. It principally causes upregulation of pro-angiogenic, proinflammatory, and vascular permeability factors such as vascular endothelial growth factor (VEGF), leading to neovascularisation. The advanced stage of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Raman, Rajiv, Ramasamy, Kim, Shah, Utkarsh
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9467443/ https://www.ncbi.nlm.nih.gov/pubmed/36106093 http://dx.doi.org/10.2147/OPTH.S374165

Ejemplares similares

Update on Management of Non-proliferative Diabetic Retinopathy without Diabetic Macular Edema; Is There a Paradigm Shift?
por: Arabi, Amir, et al.
Publicado: (2022)

Update on the Management of Diabetic Retinopathy: Anti-VEGF Agents for the Prevention of Complications and Progression of Nonproliferative and Proliferative Retinopathy
por: Bahr, Tyler A., et al.
Publicado: (2023)

The role of anti-vascular endothelial growth factor (anti-VEGF) in the management of proliferative diabetic retinopathy
por: Zhao, Yue, et al.
Publicado: (2018)

Laser versus Anti-VEGF: A Paradigm Shift for Treatment-Warranted Retinopathy of Prematurity
por: Hartnett, M. Elizabeth, et al.
Publicado: (2023)

Paradigm shift – For effective management of diabetic retinopathy and glaucoma
por: Ravilla, Thulasiraj
Publicado: (2018)

Impact of Intravitreal Anti-VEGF Therapy on Microperimetry of the Retinal Nonperfusion Areas of Patients with Proliferative Diabetic Retinopathy
por: Parravano, Mariacristina, et al.
Publicado: (2022)

The Role of Angiogenesis in the Development of Proliferative Diabetic Retinopathy: Impact of Intravitreal Anti-VEGF Treatment
por: Tremolada, Gemma, et al.
Publicado: (2012)

Combined Tractional and Rhegmatogenous Retinal Detachment in Proliferative Diabetic Retinopathy in the Anti-VEGF Era
por: Hsu, Ya-Jui, et al.
Publicado: (2014)

Potential bias of preoperative intravitreal anti-VEGF injection for complications of proliferative diabetic retinopathy
por: Takayama, Kei, et al.
Publicado: (2021)

The Angio-Fibrotic Switch of VEGF and CTGF in Proliferative Diabetic Retinopathy
por: Kuiper, Esther J., et al.
Publicado: (2008)

Simulation of long-term impact of intravitreal anti-VEGF therapy on patients with severe non-proliferative diabetic retinopathy
por: Nguyen, Quan Dong, et al.
Publicado: (2023)

microRNA Expression Profile in the Vitreous of Proliferative Diabetic Retinopathy Patients and Differences from Patients Treated with Anti-VEGF Therapy
por: Friedrich, Julian, et al.
Publicado: (2020)

Comparative Analysis of the Effects of the Anti-VEGF Drug and Glucocorticoid by Injection before the End of Vitrectomy for Proliferative Diabetic Retinopathy
por: Zhao, Haijin, et al.
Publicado: (2021)

Combined Use of Anti-VEGF Drugs Before and During Pars Plana Vitrectomy for Severe Proliferative Diabetic Retinopathy
por: Sun, Xincheng, et al.
Publicado: (2023)

Extracellular SOD and VEGF are increased in vitreous bodies from proliferative diabetic retinopathy patients
por: Izuta, Hiroshi, et al.
Publicado: (2009)

VEGF-Independent Activation of Müller Cells by the Vitreous from Proliferative Diabetic Retinopathy Patients
por: Rezzola, Sara, et al.
Publicado: (2021)

Diabetic retinopathy: A right time to intervene
por: Raman, Rajiv, et al.
Publicado: (2020)

Retracted: Comparative Analysis of the Effects of the Anti-VEGF Drug and Glucocorticoid by Injection before the End of Vitrectomy for Proliferative Diabetic Retinopathy
por: and Alternative Medicine, Evidence-Based Complementary
Publicado: (2023)

Anti-VEGF therapy prevents Müller intracellular edema by decreasing VEGF-A in diabetic retinopathy
por: Wang, Tianqin, et al.
Publicado: (2021)

Leukostasis retinopathy treated with Anti-VEGF therapy
por: Shakibai, Nasim, et al.
Publicado: (2020)

Moving Past Anti-VEGF: Novel Therapies for Treating Diabetic Retinopathy
por: Bolinger, Mark T., et al.
Publicado: (2016)

Proliferative diabetic retinopathy and relations among antioxidant activity, oxidative stress, and VEGF in the vitreous body
por: Izuta, Hiroshi, et al.
Publicado: (2010)

Vitreous and Plasma VEGF Levels as Predictive Factors in the Progression of Proliferative Diabetic Retinopathy after Vitrectomy
por: Wang, Jiaxing, et al.
Publicado: (2014)

Commentary: Role of hyperhomocysteinemia in proliferative diabetic retinopathy: A case–control study
por: Ramasamy, Kim, et al.
Publicado: (2018)

Galectin-1 expression imprints a neurovascular phenotype in proliferative retinopathies and delineates responses to anti-VEGF
por: Ridano, Magali E., et al.
Publicado: (2017)

Diabetic Retinopathy and VEGF
por: Gupta, N, et al.
Publicado: (2013)

Vascular endothelial growth factor inhibition and proliferative diabetic retinopathy, a changing treatment paradigm?
por: Wu, Lihteh, et al.
Publicado: (2019)

Heritability of Proliferative Diabetic Retinopathy
por: Hietala, Kustaa, et al.
Publicado: (2008)

Proliferative diabetic retinopathy in acromegaly
por: Malhotra, Chintan
Publicado: (2010)

Telemedicine in Diabetic Retinopathy: Current Status and Future Directions
por: Das, Taraprasad, et al.
Publicado: (2015)

Diabetic retinopathy screening guidelines in India: All India Ophthalmological Society diabetic retinopathy task force and Vitreoretinal Society of India Consensus Statement
por: Raman, Rajiv, et al.
Publicado: (2021)

Prevalence and incidence of visual impairment in patients with proliferative diabetic retinopathy in India
por: Khan, Rehana, et al.
Publicado: (2020)

Novel therapies for proliferative retinopathies
por: Martinez-Alejo, Juan Manuel, et al.
Publicado: (2022)

Paradigm Shift or Shifting Paradigm for Type 1 Diabetes
por: Nakayama, Maki, et al.
Publicado: (2012)

Intravitreal Bevacizumab as Anti-Vascular Endothelial Growth Factor in the Management of Complications of Proliferative Diabetic Retinopathy
por: Fernando Arevalo, J.
Publicado: (2013)

Proliferative and inflammatory factors in the vitreous of patients with proliferative diabetic retinopathy
por: Chernykh, VV, et al.
Publicado: (2015)

TGF-β Serum Levels in Diabetic Retinopathy Patients and the Role of Anti-VEGF Therapy
por: Bonfiglio, Vincenza, et al.
Publicado: (2020)

Angiogenic Potential of Vitreous from Proliferative Diabetic Retinopathy and Eales' Disease Patients
por: Murugeswari, Ponnalagu, et al.
Publicado: (2014)

Growth Factors in Proliferative Diabetic Retinopathy
por: Khan, Zia Ali, et al.
Publicado: (2003)

Candidate Genes for Proliferative Diabetic Retinopathy
por: Petrovič, Daniel
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_qg4cqa0a1o1bobrv9as2lg8639